{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:53:02Z","timestamp":1778788382579,"version":"3.51.4"},"reference-count":71,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre of Poland","doi-asserted-by":"publisher","award":["#UMO-2017\/25\/B\/NZ5\/ 02848"],"award-info":[{"award-number":["#UMO-2017\/25\/B\/NZ5\/ 02848"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["#503\/1-156-04\/503-11-001"],"award-info":[{"award-number":["#503\/1-156-04\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["#564\/1-000-00\/564-20-023"],"award-info":[{"award-number":["#564\/1-000-00\/564-20-023"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2018,12,6]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Colorectal cancer (CRC) is one of the most common cancers in both men and women. Approximately\none-third of patients do not survive five years from diagnosis, which indicates the need for\ntreatment improvement, also through new ways of drug delivery. A possible strategy to increase treatment\nefficacy is the use of liposomal formulation, which allows delivering both hydrophobic and hydrophilic\ncompounds with better biocompatibility and reduced side-effects. Liposomal formulations\nshowed better antitumor activity, longer drug accumulation and no cytotoxic effect on normal cells\nwhen compared to free drugs. In this review, we will present liposomal preparations studied in CRC in\nvitro and in vivo. We will focus on the advantages of liposomal delivery over conventional therapy as\nwell as modifications which increase specificity, drug accumulation and efficacy. Moreover, we will\ndiscuss formulations investigated in clinical trials. Liposomal delivery has a great potential in overcoming\ncurrent limitations of cancer therapy and development of this system gives new perspectives in\nCRC treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557518666180903150928","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T08:19:22Z","timestamp":1536049162000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["New Trends in Liposome-based Drug Delivery in Colorectal Cancer"],"prefix":"10.2174","volume":"19","author":[{"given":"Julia B.","family":"Krajewska","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Bartoszek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Fichna","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Ferlay J.","year":"","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. , , GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality\nWorldwide: IARC CancerBase. No. 11 [Internet].,"},{"key":"ref=2","author":"Howlader N.","unstructured":", Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A.  , , SEER\nCancer Statistics Review, 1975-2014, National Cancer Institute.\nBethesda, MD,  Based on\nNovember 2016 SEER Data Submission, Posted to the SEER Web\nSite, April 2017.\n                     2017,\npp 1-101.,"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.msec.2016.11.073","volume":"71","author":"Zununi Vahed S.","year":"2017","unstructured":"Zununi Vahed S, Salehi R, Davaran S, Sharifi S. Mater Sci Eng C, Liposome-Based Drug Co-Delivery Systems in Cancer Cells.,, 2017, 71,, 1327-1341,","journal-title":"Mater Sci Eng C"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"Allen T.M.","year":"2013","unstructured":"Allen TM, Cullis PR. Adv Drug Deliv Rev, Liposomal drug delivery systems: From concept to clinical applications.,, 2013, 65,, 36-48,","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=5","first-page":"245","volume":"2","author":"Udofot O.","year":"2015","unstructured":"Udofot O, Affram K, Israel B, Agyare E. Integr Cancer Sci Ther, Cytotoxicity of 5-fluorouracil-loaded ph-sensitive liposomal nanoparticles in colorectal cancer cell lines.,, 2015, 2,, 245-252,","journal-title":"Integr Cancer Sci Ther"},{"key":"ref=6","volume":"2","author":"Udofot O.","year":"2016","unstructured":"Udofot O, Affram K, Smith T, Tshabe B, Krishnan S, Sachdeva M, Agyare E. J Nat Sci, Pharmacokinetic, Biodistribution and therapeutic efficacy of 5-fluorouracil-loaded ph-sensitive pegylated liposomal nanoparticles in HCT-116 tumor bearing mouse.,, 2016, 2,, 245-,","journal-title":"J Nat Sci"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lfs.2017.12.026","volume":"194","author":"Moghimipour E.","year":"2018","unstructured":"Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, Dorkoosh FA, Handali S. Life Sci, Transferrin targeted liposomal 5-fluorouracil induced apoptosis via mitochondria signaling pathway in cancer cells.,, 2018, 194,, 104-110,","journal-title":"Life Sci"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.bjc.6603970","volume":"97","author":"Fanciullino R.","year":"2007","unstructured":"Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J. Br J Cancer, \n                        In Vitro and in vivo Reversal of resistance to 5-Fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.,, 2007, 97,, 919-926,","journal-title":"Br J Cancer"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s11095-012-0967-2","volume":"30","author":"Fanciullino R.","year":"2013","unstructured":"Fanciullino R, Mollard S, Giacometti S, Berda-Haddad Y, Chefrour M, Aubert C, Iliadis A, Ciccolini J. Pharm Res, \n                        In Vitro and in vivo Evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-Fu: Impact on efficacy and toxicity.,, 2013, 30,, 1281-1290,","journal-title":"Pharm Res"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"e62349","DOI":"10.1371\/journal.pone.0062349","volume":"8","author":"Hare J.I.","year":"2013","unstructured":"Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN. PLoS One, Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore CTM) and 5-Fluorouracil.,, 2013, 8,, e62349-,","journal-title":"PLoS One"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2016.07.022","volume":"238","author":"Zhang B.","year":"2016","unstructured":"Zhang B, Wang T, Yang S, Xiao Y, Song Y, Zhang N, Garg S. J Control Release, Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.,, 2016, 238,, 10-21,","journal-title":"J Control Release"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3892\/or.2014.3336","volume":"32","author":"Yang C.","year":"2014","unstructured":"Yang C, Fu Z-X. Oncol Rep, PEG-Liposomal oxaliplatin combined with nuclear factor-\u03bab inhibitor (pdtc) induces apoptosis in human colorectal cancer cells.,, 2014, 32,, 1617-1621,","journal-title":"Oncol Rep"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.3892\/ol.2016.4481","volume":"11","author":"Li K.","year":"2016","unstructured":"Li K. Oncol Lett, ZHOU, Z.-Y.; JI, P.-P.; LUO, H.-S. Knockdown of \u03b2-Catenin by SiRNA influences proliferation, apoptosis and invasion of the colon cancer cell line SW480.,, 2016, 11,, 3896-3900,","journal-title":"Oncol Lett"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijpharm.2017.02.020","volume":"525","author":"Bochicchio S.","year":"2017","unstructured":"Bochicchio S, Dapas B, Russo I, Ciacci C, Piazza O, De Smedt S, Pottie E, Barba AA, Grassi G. Int J Pharm, \n                        In vitro and Ex vivo Delivery of tailored SiRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer.,, 2017, 525,, 377-387,","journal-title":"Int J Pharm"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/1061186X.2012.680960","volume":"20","author":"Mamot C.","year":"2012","unstructured":"Mamot C, Ritschard R, Wicki A, K\u00fcng W, Schuller J, Herrmann R, Rochlitz C. J Drug Target, Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR- Overexpressing tumor cells.,, 2012, 20,, 422-432,","journal-title":"J Drug Target"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2015.05.271","volume":"210","author":"Zalba S.","year":"2015","unstructured":"Zalba S, Contreras AM, Haeri A, ten Hagen TLM, Navarro I, Koning G, Garrido MJ. J Control Release, Cetuximab-Oxaliplatin-Liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.,, 2015, 210,, 26-38,","journal-title":"J Control Release"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/138920111796117328","volume":"12","author":"Garg A.","year":"2011","unstructured":"Garg A, Kokkoli E. Curr Pharm Biotechnol, PH-Sensitive PEGylated liposomes functionalized with a fibronectin-mimetic peptide show enhanced intracellular delivery to colon cancer cell.,, 2011, 12,, 1135-1143,","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/sj.onc.1205347","volume":"21","author":"Oku N.","year":"2002","unstructured":"Oku N, Asai T, Watanabe K, Kuromi K, Nagatsuka M, Kurohane K, Kikkawa H, Ogino K, Tanaka M, Ishikawa D, Tsukada H, Momose M, Nakayama J, Taki T. Oncogene, Anti-Neovascular therapy using novel peptides homing to angiogenic vessels.,, 2002, 21,, 2662-2669,","journal-title":"Oncogene"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-5793(02)02821-1","volume":"520","author":"Asai T.","year":"2002","unstructured":"Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N. FEBS Lett, Anti-Neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.,, 2002, 520,, 167-170,","journal-title":"FEBS Lett"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2004.07.033","volume":"100","author":"Maeda N.","year":"2004","unstructured":"Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N. J Control Release, Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.,, 2004, 100,, 41-52,","journal-title":"J Control Release"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2005.02.030","volume":"296","author":"Shimizu K.","year":"2005","unstructured":"Shimizu K, Asai T, Fuse C, Sadzuka Y, Sonobe T, Ogino K, Taki T, Tanaka T, Oku N. Int J Pharm, Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.,, 2005, 296,, 133-141,","journal-title":"Int J Pharm"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1349-7006.2008.00758.x","volume":"99","author":"Asai T.","year":"2008","unstructured":"Asai T, Miyazawa S, Maeda N, Hatanaka K, Katanasaka Y, Shimizu K, Shuto S, Oku N. Cancer Sci, Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.,, 2008, 99,, 1029-1033,","journal-title":"Cancer Sci"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(03)00240-2","volume":"91","author":"Schiffelers R.M.","year":"2003","unstructured":"Schiffelers RM, Koning GA, Ten Hagen TLM, Fens MHAM, Schraa AJ, Janssen APCA, Kok RJ, Molema G, Storm G. J Control Release, Anti-Tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.,, 2003, 91,, 115-122,","journal-title":"J Control Release"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","volume":"312","author":"Shibuya M.","year":"2006","unstructured":"Shibuya M, Claesson-Welsh L. Exp Cell Res, Signal Transduction by VEGF Receptors in Regulation of Angiogenesis and Lymphangiogenesis.,, 2006, 312,, 549-560,","journal-title":"Exp Cell Res"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-11-1102","volume":"18","author":"Wicki A.","year":"2012","unstructured":"Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. Clin Cancer Res, Targeting tumor-associated endothelial cells: anti-vegfr2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.,, 2012, 18,, 454-464,","journal-title":"Clin Cancer Res"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2147\/IJN.S125573","volume":"12","author":"Song Z.","year":"2017","unstructured":"Song Z, Lin Y, Zhang X, Feng C, Lu Y, Gao Y, Dong C, Cyclic RGD. Int J Nanomedicine, Peptide-Modified liposomal drug delivery system for targeted oral apatinib administration: Enhanced cellular uptake and improved therapeutic effects.,, 2017, 12,, 1941-1958,","journal-title":"Int J Nanomedicine"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/js9604467","volume":"86","author":"Crosasso P.","year":"1997","unstructured":"Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L. J Pharm Sci, Antitumoral activity of liposomes and immunoliposomes containing 5- fluorouridine prodrugs.,, 1997, 86,, 832-839,","journal-title":"J Pharm Sci"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.bjc.6601341","volume":"89","author":"Hosokawa S.","year":"2003","unstructured":"Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K. Br J Cancer, Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner.,, 2003, 89,, 1545-1551,","journal-title":"Br J Cancer"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1349-7006.2004.tb02495.x","volume":"95","author":"Hamaguchi T.","year":"2004","unstructured":"Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, Shirao K, Niki H, Hosokawa S, Tagawa T, Kakizoe T. Cancer Sci, Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody gah, in colorectal cancer xenografts.,, 2004, 95,, 608-613,","journal-title":"Cancer Sci"},{"key":"ref=30","first-page":"4282","volume":"62","author":"Lee C.M.","year":"2002","unstructured":"Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M. Cancer Res, Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo.,, 2002, 62,, 4282-4288,","journal-title":"Cancer Res"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1615\/CritRevImmunol.v21.i1-3.200","volume":"21","author":"Kawakami K.","year":"2001","unstructured":"Kawakami K, Puri RK, Kawakami M. Crit Rev Immunol, Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.,, 2001, 21,, 12-,","journal-title":"Crit Rev Immunol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/carcin\/bgq044","volume":"31","author":"Koller F.L.","year":"2010","unstructured":"Koller FL, Hwang DG, Dozier EA, Fingleton B. Carcinogenesis, Epithelial interleukin-4 receptor expression promotes colon tumor growth.,, 2010, 31,, 1010-1017,","journal-title":"Carcinogenesis"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1080\/15384047.2015.1095397","volume":"4047","author":"Yang C.","year":"2015","unstructured":"Yang C, Liu H, Tsai Y, Tseng J, Liang S, Chen C, Lian W, Wei M, Lu M, Lu R. Cancer Biol Ther, Doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor ef fi cacy in murine colorectal cancer.,, 2015, 4047,, 1641-1650,","journal-title":"Cancer Biol Ther"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijbiomac.2015.09.052","volume":"82","author":"Bansal D.","year":"2016","unstructured":"Bansal D, Gulbake A, Tiwari J, Jain SK. Int J Biol Macromol, Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer.,, 2016, 82,, 687-695,","journal-title":"Int J Biol Macromol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2016.08.036","volume":"512","author":"Fang T.","year":"2016","unstructured":"Fang T, Dong Y, Zhang X, Xie K, Lin L, Wang H. Int J Pharm, Integrating a novel SN38 prodrug into the pegylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.,, 2016, 512,, 39-48,","journal-title":"Int J Pharm"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.7150\/thno.21688","volume":"7","author":"Blocker S.J.","year":"2017","unstructured":"Blocker SJ, Douglas KA, Polin LA, Lee H, Hendriks BS, Lalo E, Chen W, Shields AF. Theranostics, Liposomal64Cu-PET imaging of anti-vegf drug effects on liposomal delivery to colon cancer xenografts.,, 2017, 7,, 4229-4239,","journal-title":"Theranostics"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2018.01.039","volume":"540","author":"Riahi M.M.","year":"2018","unstructured":"Riahi MM, Sahebkar A, Sadri K, Nikoofal-Sahlabadi S, Jaafari MR. Int J Pharm, Stable and Sustained Release Liposomal formulations of celecoxib: in vitro and in vivo anti-tumor evaluation.,, 2018, 540,, 89-97,","journal-title":"Int J Pharm"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/1061186X.2017.1339192","volume":"26","author":"Sun D.","year":"2018","unstructured":"Sun D, Zhao L, Lin J, Zhao Y, Zheng Y. J Drug Target, Cationic liposome Co-encapsulation of SMAC mimetic and ZVAD using a novel lipid bilayer fusion loaded with mlkl-pdna for tumour inhibition in vivo.,, 2018, 26,, 45-54,","journal-title":"J Drug Target"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/lsm.22312","volume":"47","author":"Peng P.C.","year":"2015","unstructured":"Peng PC, Hong RL, Tsai YJ, Li PT, Tsai T, Chen CT. Lasers Surg Med, Dual-effect liposomes encapsulated with doxorubicin and chlorin E6 augment the therapeutic effect of tumor treatment.,, 2015, 47,, 77-87,","journal-title":"Lasers Surg Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/aps.2017.10","volume":"38","author":"Kang X.J.","year":"2017","unstructured":"Kang XJ, Wang HY, Peng HG, Chen BF, Zhang WY, Wu AH, Xu Q, Huang YZ. Acta Pharmacol Sin, Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for Drug-resistant colon cancer therapy.,, 2017, 38,, 885-896,","journal-title":"Acta Pharmacol Sin"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.trsl.2017.04.001","volume":"185","author":"Kokuryo D.","year":"2017","unstructured":"Kokuryo D, Aoki I, Yuba E, Kono K, Aoshima S, Kershaw J, Saga T. Transl Res, Evaluation of a combination tumor treatment using thermo-triggered liposomal drug delivery and carbon ion irradiation.,, 2017, 185,, 24-33,","journal-title":"Transl Res"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ultrasmedbio.2015.12.005","volume":"42","author":"Jeong H.S.","year":"2016","unstructured":"Jeong HS, Hwang H, Oh PS, Kim EM, Lee TK, Kim M, Kim HS, Lim ST, Sohn MH, Jeong HJ. Ultrasound Med Biol, Effect of high-intensity focused ultrasound on drug release from doxorubicin-loaded PEGylated liposomes and therapeutic effect in colorectal cancer murine models.,, 2016, 42,, 947-955,","journal-title":"Ultrasound Med Biol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2011.05.005","volume":"153","author":"Riviere K.","year":"2011","unstructured":"Riviere K, Kieler-Ferguson HM, Jerger K, Szoka FC. J Control Release, Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.,, 2011, 153,, 288-296,","journal-title":"J Control Release"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/cas.13305","volume":"108","author":"Shimizu T.","year":"2017","unstructured":"Shimizu T, Abu Lila AS, Nishio M, Doi Y, Ando H, Ukawa M, Ishima Y, Ishida T. Cancer Sci, Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.,, 2017, 108,, 1864-1869,","journal-title":"Cancer Sci"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.2147\/IJN.S135968","volume":"12","author":"Brody L.P.","year":"2017","unstructured":"Brody LP, Sahuri-Arisoylu M, Parkinson JR, Parkes HG, So PW, Hajji N, Thomas E, Frost GS, Miller AD, Bell JD. Int J Nanomedicine, Cationic Lipid-Based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects.,, 2017, 12,, 6677-6685,","journal-title":"Int J Nanomedicine"},{"key":"ref=46","first-page":"4701","volume":"34","author":"Ichihara H.","year":"2014","unstructured":"Ichihara H, Nakagawa S, Matsuoka Y, Yoshida K, Matsumoto Y, Ueoka R. Anticancer Res, Nanotherapy with hybrid liposomes for colorectal cancer along with apoptosis in vitro and in vivo.,, 2014, 34,, 4701-4708,","journal-title":"Anticancer Res"},{"key":"ref=47","author":"","unstructured":", .  , , Liposomal SN-38 in Treating Patients With Metastatic Colorectal\nCancer. NCT00311610\n                    \n                \n                 (accessed Apr 14, 2018).,"},{"key":"ref=48","author":"","unstructured":", .  , , Celator Pharmaceuticals. Multicenter Study Of CPX-1 (Irinotecan\nHCl: Floxuridine) Liposome Injection In Patients With Advanced\nColorectal Cancer. NCT00361842 \n                    \n                \n                 (accessed Apr 14, 2018).,"},{"key":"ref=49","author":"","unstructured":", .  , , GERCOR. Liposome-encapsulated irinotecan hydrochloride PEP02\nor irinotecan hydrochloride, leucovorin calcium, and fluorouracil as\nsecond-line therapy in treating patients with metastatic colorectal\ncancer (PEPCOL). NCT01375816 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=50","author":"","unstructured":", .  , , Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal\nAblation (RFA) in Treatment of Metastatic Colorectal\nCancer(mCRC). NCT01464593 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=51","author":"","unstructured":", .  , , Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC\nRefractory to 1st-line Oxaliplatin Base Therapy. NCT00940758 \n                    \n                 (accessed Apr 14,\n2018).,"},{"key":"ref=52","author":"","unstructured":", .  , , Intravenously Administered Pegylated Liposomal Mitomycin-C\nLipid-based Prodrug (PROMITIL) in Cancer Patients With Solid\nTumors. NCT01705002 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=53","author":"","unstructured":", .  , , A Safety and Effectiveness Study of Aroplatin in Patients With\nAdvanced Colorectal Cancer Resistant to Standard Therapies.\nNCT00043199 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=54","author":"","unstructured":", .  , , Aroplatin and Capecitabine in Patients With Advanced Colorectal\nCancer Resistant to Standard Therapies. NCT00081536 \n                    \n                 (accessed Apr 14,\n2018).,"},{"key":"ref=55","author":"","unstructured":", .  , , Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and\nRucaparib in Treating Patients With Metastatic Pancreatic,\nColorectal, Gastroesophageal, or Biliary Cancer. NCT03337087 \n                    \n                 (accessed Apr 14,\n2018).,"},{"key":"ref=56","author":"","unstructured":", .  , , The Effect of Exparel on Post Operative Pain and Narcotic Use\nAfter Colon Surgery. NCT02052557 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=57","author":"","unstructured":", .  , , A Safety and Effectiveness Study of Aroplatin in Patients With\nAdvanced Solid Malignancies. NCT00057395 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=58","author":"","unstructured":", .  , , TAS102 in Combination With NAL-IRI in Advanced GI Cancers.\nNCT03368963 \n                    \n                 (accessed Apr 14, 2018).,"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1078-0432.CCR-08-0515","volume":"15","author":"Batist G.","year":"2009","unstructured":"Batist G, Gelmon KA, Chi KN, Miller WH, Chia SKL, Mayer LD, Swenson CE, Janoff AS, Louie AC. Clin Cancer Res, Safety, Pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.,, 2009, 15,, 692-700,","journal-title":"Clin Cancer Res"},{"key":"ref=60","first-page":"1489","volume":"26","author":"Stathopoulos G.P.","year":"2006","unstructured":"Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Anticancer Res, Liposomal oxaliplatin in the treatment of advanced cancer: A phase I study.,, 2006, 26,, 1489-1493,","journal-title":"Anticancer Res"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-05-0104","volume":"11","author":"Beutel G.","year":"2005","unstructured":"Beutel G. Clin Cancer Res, Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.,, 2005, 11,, 5487-5495,","journal-title":"Clin Cancer Res"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.bjc.6603267","volume":"95","author":"Falk S.","year":"2006","unstructured":"Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D. Br J Cancer, Ajani. J. Multicentre phase II pharmacokinetic and pharmacodynamic study of osi-7904l in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.,, 2006, 95,, 450-456,","journal-title":"Br J Cancer"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2147\/DDDT.S85567","volume":"9","author":"Suenaga M.","year":"2015","unstructured":"Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Drug Des Devel Ther, Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.,, 2015, 9,, 3099-3108,","journal-title":"Drug Des Devel Ther"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00280-007-0509-5","volume":"61","author":"Clamp A.R.","year":"2008","unstructured":"Clamp AR, Sch\u00f6ffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J. Cancer Chemother Pharmacol, A Phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.,, 2008, 61,, 579-585,","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/cam4.491","volume":"4","author":"Golan T.","year":"2015","unstructured":"Golan T, Grenader T, Ohana P, Amitay Y, Shmeeda H, La-Beck NM, Tahover E, Berger R, Gabizon AA. Cancer Med, Pegylated liposomal mitomycin c prodrug enhances tolerance of mitomycin C: A phase 1 study in advanced solid tumor patients.,, 2015, 4,, 1472-1483,","journal-title":"Cancer Med"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00000421-200102000-00019","volume":"24","author":"Shields A.F.","year":"2001","unstructured":"Shields AF, Lange LM, Zalupski MM. Am J Clin Oncol, Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer.,, 2001, 24,, 96-98,","journal-title":"Am J Clin Oncol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00000421-199412000-00009","volume":"17","author":"Eckardt J.R.","year":"1994","unstructured":"Eckardt JR, Campbell E, Burris HA, Weiss GR, Rodriguez GI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenberg ML. Am J Clin Oncol, A phase II trial of daunoxome, liposome-encapsulated daunorubicin, in patients with metastatic adeno-carcinoma of the colon.,, 1994, 17,, 498-501,","journal-title":"Am J Clin Oncol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-006-0235-4","volume":"58","author":"Dragovich T.","year":"2006","unstructured":"Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. Cancer Chemother Pharmacol, A phase 2 trial of the liposomal dach platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.,, 2006, 58,, 759-764,","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2217\/fon.13.146","volume":"9","author":"Gentile E.","year":"2013","unstructured":"Gentile E, Cilurzo F, Di Marzio L, Carafa M, Anna Ventura C, Wolfram J, Paolino D, Celia C. Future Oncol, Liposomal Chemotherapeutics.,, 2013, 9,, 1849-1859,","journal-title":"Future Oncol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0885328215578111","volume":"30","author":"Tila D.","year":"2015","unstructured":"Tila D, Ghasemi S, Yazdani-Arazi SN, Ghanbarzadeh S. J Biomater Appl, Functional liposomes in the cancer-targeted drug delivery.,, 2015, 30,, 3-16,","journal-title":"J Biomater Appl"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"Sercombe L.","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Front Pharmacol, Advances and challenges of liposome assisted drug delivery.,, 2015, 6,, 1-13,","journal-title":"Front Pharmacol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T20:37:32Z","timestamp":1569357452000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165079\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557518666180903150928","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}